Intravesical chemotherapy using heat energy in patiens with urothelial carcinoma of the urinary bladder

Czech version

Authors: Antonín Brisuda; Marek Babjuk; Jozef Stolz
Authors‘ workplace: Urologická klinika 2. LF UK a FN Motol, Praha
Published in: Ces Urol 2017; 21(2): 122-128
Category: Review article

Overview

Major statement:
The authors present an overview on intravesical termotherapy using heat energy in treatment of patients with non-muscle invasive bladder cancer. Furthermore, their own experience with this method is presented.

Intravesical chemotherapy currently represents an alternative treatment in patiens with high risk non-muscle invasive urothelial carcinoma failing other intravesical treatment or refusing radical cystectomy. Substitution of BCG instillation during BCG shortage represents another indication. Currently, there are long-term data on chemohyperthermia Synergo available (heat energy applied to bladder wall using radiofrequency). Termotherapy is a new method connecting warming up of the chemotherapy agent and its recirculation inside the bladder. Better cell penetration is achieved in both systems. Both methods have not become standard clinical practice yet. In this overview article, a single site experience with both procedures is presented.

KEY WORDS:
Urinary bladder carcinoma, non-muscle-invasive bladder cancer, intravesical chemotherapy, termotherapy, chemohyperthermy.

Sources

1. Mužík J, Dušek L, Babjuk M, et al. Uroweb – webový portál pro analýzu a vizualizaci epidemiologie, diagnostiky a léčby urologických malignit [online]. Masarykova univerzita, Brno, 2017. [cit. 2017–02–16]. Dostupný z WWW: http://www.uroweb.cz. ISSN 1804–6371. Verze 1.6d.

2. Pešl M, Soukup V, Babjuk M, et al. Hodnocení významu klinicko-patologických prognostických faktorů u nádorů močového měchýře neinfiltrujících svalovinu. Ces Urol 2011; 15(4): 222–228.

3. Dvořáček J, Babjuk M. Onkourologie. Praha: Galén, Karolinum 2005, 589 s., ISBN 80–7262–349–4 (Galén), 80–246–1108–2 (Karolinum).

4. Babjuk M, Burger M, Compérat E, et al. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2016. Eur Urol. 2017 Mar; 71(3): 447–461.

5. Sylvester RJ, Oosterlinck W, Holmang S, et al. Systematic review and individual patient data meta‑analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa‑pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol. 2016 Feb; 69(2): 231–244.

6. Järvinen R, Kaasinen E, Sankila A, Rintala E. FinnBladder Group. Long‑term efficacy of maintenance bacillus Calmette‑Guerin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow‑up. Eur Urol, 2009; 56: 260.

7. Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus calmette.guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta.analysis of the published results of randomized clinical trials. J Urol. 2005; 174: 86.

8. Malmstrom PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta.analysis of the long.term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette.Guerin for non.muscle.invasive bladder cancer. Eur Urol 2009; 56: 247.

9. Colombo R1, Da Pozzo LF, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol. 2003 Dec 1; 21(23): 4270.4276.

10. Colombo R, Salonia A, Leib Z, Pavone.Macaluso M, Engelstein D. Long.term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin.C alone as adjuvant treatment for non.muscle.invasive bladder cancer (NMIBC). BJU Int. 2011; 107: 912.918.

11. Internetovy portal www.synergo.medical. com.

12. Lammers RJ, Witjes JA, Inman BA, et al. The role of a combined regimen with intrave sical chemotherapy and hyperthermia in the management of non.muscle.invasive bladder cancer: a systematic review. Eur Urol. 2011; 60: 81.93.

13. Halachmi S, Moskovitz B, Maffezzini M, et al. Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder. Urol Oncol. 2011 May.Jun; 29(3): 259.264.

14. Colombo R, Da Pozzo LF, Lev A, et al. Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for select multifocal and unresectable superficial bladder tumors. J Urol. 1998; 159: 783.787.

15. Arends TJ, Nativ O, Maffezzini M, et al. Results of a randomised controlled trial comparing intravesical chemohyperthermia with Mitomycin C versus Bacillus Calmette.Guerin for adjuvant treatment of patients with intermediate- and high.risk non.muscle.invasive bladder cancer. Eur Urol. 2016 Jun; 69(6): 1046.1052.

16. Sousa A, Pineiro I, Rodriguez S, et al. Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate.high.risk non.muscle.invasive bladder cancer. Int J Hyperthermia. 2016 Jun; 32(4): 374.380.